Peptide Database

Browse and search our comprehensive peptide database. Click any peptide for detailed information including protocols, benefits, and side effects.

All Healing Weight Loss Cognitive function Longevity Immune system Muscles Skin Sleep Mitochondrial Mood Energy Bones Focus Pain

Humanin

30.00 minutes
Longevity Immune system Cognitive function Mitochondrial

Also known as Humanin - HN. There is a modified/concentrated version Humanin G (HN-G).

Key benefits:
• Protects mitochondria from oxidative stress
• Used in treatment of bone osteoporosis, cardiovascular diseases, diabetes mellitus, and neurodegenerative diseases

MOTS-C

Unknown
Mitochondrial Energy Weight Loss Longevity

Key benefits:
• Significantly decreases fat accumulation in the liver
• Improves cardiovascular health

Retatrutide

144.00 hours
Weight Loss Longevity Mitochondrial

Triple hormone receptor agonist (GLP-1 / GIP / glucagon) by Eli Lilly. Code name LY3437943. Phase 3 as of 2024. Not yet FDA approved — available only through clinical trials.

Key benefits:
• Triple action: stimulates GLP-1 and GIP receptors (satiety, insulin sensitization) plus glucagon receptors (increased energy expenditure, hepatic fat clearance)
• Up to 22.8-24.2% body weight loss at 48 weeks in Phase 2 (8-12 mg doses)

SS-31

Unknown
Mitochondrial Healing Focus Longevity

AKA Elampretide.

Key benefits:
• Repair cells
• Macular degeneration

Semaglutide

165.00 hours
Weight Loss Longevity Mitochondrial

FDA-approved GLP-1 receptor agonist. Marketed as Ozempic (type 2 diabetes) and Wegovy/Wegovy HD (chronic weight management). Weekly subcutaneous injection.

Key benefits:
• Activates GLP-1 receptors to increase satiety and reduce hunger
• Clinically proven ~15% average weight loss on Wegovy (2.4 mg weekly) over 68 weeks

Tirzepatide

120.00 hours
Weight Loss Longevity Mitochondrial

Dual GIP/GLP-1 receptor agonist. Marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Weekly subcutaneous injection by Eli Lilly.

Key benefits:
• Dual action on GIP and GLP-1 receptors — stronger appetite suppression and satiety signaling than GLP-1 alone
• Average 15-22.5% body weight loss over 72 weeks at highest dose (Zepbound)